Circular ANRIL promotes the activation of the p53 protein, which leads to an increase in apoptosis, while linear ANRIL inhibits the apoptosis process by repressing CDKN2A and CDKN2B, which are tumor suppressors. Here, CDKN2B-AS1 is linked to neoplasm.